secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001790340-23-000054
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering Q3 net loss $0.43/share; Phase 2a for IMM-1-104 expanded to 5 arms
------------------------------------------------------------------------------

- Net loss $12.6M ($0.43/sh) vs $12.8M ($0.49/sh) in Q3 2022.
- Cash $97.2M at Sept 30, 2023 ($105.5M at Dec 31, 2022); runway into 2025.
- Phase 1 dose evaluation of IMM-1-104 ~2/3 enrolled; no DLTs; Phase 2 dose recommendation expected early 2024.
- Phase 2a expanded to 5 arms: 3 monotherapy (PDAC, melanoma, NSCLC) and 2 combinations (mFOLFIRINOX, gem/nab-paclitaxel); first patient dosing early 2024.
- IND for IMM-6-415 on track for Q4 2023; Phase 1/2a to include RAS and RAF mutant disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034023000054/0001790340-23-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034023000054/imrx-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001790340-23-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer